Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopartners Holdings has terminated its 10-year agreement for the license and supply of the Medical House's GH1 reusable, spring powered, needle-free delivery system for the delivery of its human growth hormone product, Valtropin.
Subscribe to our email newsletter
In 2006, Biopartners initiated a comparative bioavailability/bioequivalence study in volunteers to assess Valtropin delivered by the Medical House’s GH1. The Medical House has never been able to supply Biopartners with the GH1 devices needed to perform this clinical study. Therefore, Biopartners terminated the collaboration.
Jean-Noel Treilles, CEO of Biopartners, said: “Having received EMEA approval in April 2006, we had planned to launch Valtropin at the end of that year. However, with the GH1 device not functioning correctly, we have had to end our agreement with the Medical House in order to seek a suitable and robust alternative delivery system.”